

Figure S1. Effect of PMT on CD25 expression in lymphocytes of the CPA-treated mice. (A) Representative flow cytometry dot plots showing CD25 expression in thymic lymphocytes from each experimental group. (B) Quantification of the percentage of $CD25^+$ lymphocytes across the different groups. Data are expressed as the means ± SEM (n = 6). Statistical significance was analyzed using one-way ANOVA followed by Tukey's post hoc test. Note: $^{\#\#\#\#}p < 0.0001$ vs. the normal group; $^{*}p < 0.05$ and $^{****}p < 0.0001$ vs. the CPA group.




Figure S2. Effect of PMT on spleen size and spleen index in the CPA-treated mice. (A) Representative images of spleen tissues from each group at 14 days. White scale bar = 200 μm. (B) Spleen index (spleen weight / body weight ratio) across the different treatment groups. Data are presented as the means ± SEM (n = 6). Statistical significance was determined using one-way ANOVA followed by Tukey's post hoc test. Note: $^{###}p < 0.001$ vs. the normal group.

Table S1. Comparison of immunosuppressive effects of the different CPA doses in mice.

Group	Initial Body Weight (g)	Final Body Weight (g)	Spleen Weight (mg)	Thymus Weight (mg)	Liver Weight (g)
Control	22.42±0.63	23.25±1.26	70 ± 1	50 ± 10	1.22±0.05
Cyclophosphamide 12.5 mg/kg	21.92±0.45	23.25±0.50	60 ± 3	50 ± 4	1.13±0.03
Cyclophosphamide 70 mg/kg	22.33±0.16	23.00±1.41	80 ± 5**	50 ± 3	1.05±0.14
Cyclophosphamide 150 mg/kg	21.53±0.47	21.50±0.58	90 ± 4***	20 ± 4***	1.00±0.14